“It is generally recognized that poor solubility is one of the most frequently encountered difficulties in the field of pharmaceutics.” – Kumar and Singh. American Journal of Pharmacological Sciences. 2013; 4: 67.
Many challenges slow the pace of drug development. One such challenge is drug solubility. Poor solubility causes low bioavailability and a decreased chance of drug administration resulting positive clinical outcomes.
Poor solubility can cause low bioavailability. “Aqueous solubility is one of the most influencing factors when it comes to bioavailability of the drugs. It is the main key for drug effectiveness,” according to a 2013 article in the Journal of Developing Drugs. Drug absorption relies on solubility, as well as permeability. Poor dissolution in the fluids of the gastrointestinal tract can affect the bioavailability and efficacy of the drug.
Poor solubility can lower a drug’s chance of marking it to market. “Among all newly discovered chemical entities, about 40% are lipophilic and fail to reach the market due to their poor water solubility,” according to a 2017 article in Drug Development & Delivery. The article continues to state that in the future, that number is expected to rise to 90 percent. This is a problem because drug developers waste time and money on medications that will never make it to patients.
Poor solubility can lead to low bioavailability and decrease the likelihood of a drug making it to market. Orbis Biosciences leverages its Precision Particle Fabrication technology to create multiparticulate formats that can drive improvements in bioavailability.